Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $32.8 million.

  • Fulcrum Therapeutics' Net Cash Flow rose 131.84% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 159.90%. This contributed to the annual value of $32.8 million for FY2024, which is 443.56% up from last year.
  • Fulcrum Therapeutics' Net Cash Flow amounted to $32.8 million in FY2024, which was up 443.56% from -$9.5 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Net Cash Flow registered a high of $32.8 million during FY2024, and its lowest value of -$39.7 million during FY2020.
  • For the 3-year period, Fulcrum Therapeutics' Net Cash Flow averaged around $7.6 million, with its median value being -$314,000 (2022).
  • In the last 5 years, Fulcrum Therapeutics' Net Cash Flow crashed by 2,936.62% in 2023 and then skyrocketed by 443.56% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Net Cash Flow stood at -$39.7 million in 2020, then spiked by 45.44% to -$21.6 million in 2021, then skyrocketed by 98.55% to -$314,000 in 2022, then tumbled by 2,936.62% to -$9.5 million in 2023, then spiked by 443.56% to $32.8 million in 2024.